4,633 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by AGF Management Ltd.

AGF Management Ltd. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,633 shares of the company's stock, valued at approximately $632,000.

Several other large investors have also recently made changes to their positions in the business. State Street Corp raised its stake in shares of Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after acquiring an additional 539,936 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 1,859,232 shares of the company's stock worth $213,773,000 after acquiring an additional 39,610 shares in the last quarter. Braidwell LP raised its stake in shares of Neurocrine Biosciences by 20.9% during the third quarter. Braidwell LP now owns 917,674 shares of the company's stock worth $105,734,000 after acquiring an additional 158,665 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Neurocrine Biosciences by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 870,290 shares of the company's stock worth $118,795,000 after acquiring an additional 12,040 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth approximately $115,193,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 272 shares of the company's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company's stock, valued at $346,216.70. This represents a 9.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kevin Charles Gorman sold 5,844 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the sale, the director now directly owns 521,618 shares of the company's stock, valued at $60,867,604.42. The trade was a 1.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 233,178 shares of company stock valued at $33,906,594. 4.30% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

Several research firms have commented on NBIX. Bank of America decreased their price target on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Barclays lifted their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a research note on Monday, December 23rd. Guggenheim decreased their target price on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. StockNews.com raised shares of Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, March 12th. Finally, Morgan Stanley restated an "overweight" rating and set a $150.00 target price (down previously from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $165.24.

Neurocrine Biosciences Trading Up 0.6 %

NASDAQ:NBIX traded up $0.61 during mid-day trading on Wednesday, reaching $110.31. The company's stock had a trading volume of 909,987 shares, compared to its average volume of 957,453. Neurocrine Biosciences, Inc. has a 12-month low of $105.18 and a 12-month high of $157.98. The firm's fifty day moving average price is $128.62 and its two-hundred day moving average price is $125.47. The stock has a market cap of $11.00 billion, a P/E ratio of 33.53, a PEG ratio of 0.77 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its board has approved a stock buyback plan on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.